Editas Medicine, Inc.
EDIT
Positions held
Your positionsEDIT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $436.17M | Enterprise value | $240.03M | Trailing P/E | — | Forward P/E | -3.77 |
| PEG | — | Price / book | 4.14 | Beta | 2.00 | Dividend yield | 0.00% |
| Revenue growth | 2.3% | Earnings growth | — | Gross margin | -80.7% | Operating margin | -1.7% |
| Profit margin | -1.6% | ROE | -118.8% | ROA | -23.3% | Debt / equity | 0.15 |
| Current ratio | 3.19 | Free cash flow | -$44.32M | Analyst recommendation | none | Mean target | $5.90 |
| 52w high | $4.33 | 52w low | $1.66 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $11.9M | $2.8M | $24.7M | $7.5M | $3.6M | — |
| Op margin | -167.3% | -883.2% | -56.7% | -325.4% | -711.6% | — |
| Net income | -$18.2M | -$25.0M | -$5.6M | -$25.1M | -$53.2M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$19.9M | -$25.0M | -$14.0M | -$24.5M | -$25.5M | — |
- Revenue +320% vs prior quarter ($12M vs $2.8M).
- Operating margin expanded to -167.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $40.5M | $32.3M | $78.1M | $19.7M |
| Op margin | -245.2% | -739.4% | -216.6% | -1146.3% |
| Net income | -$160M | -$237M | -$153M | -$220M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$99.3M | -$239M | -$169M | -$226M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Sector Update: Healthcare Stocks Softer Late Afternoon
2026-10-08 · Sector Update: Healthcare
2026-10-08 · Update: Editas Medicine Shares Rise After Australia Clears Phase 1/2 Trial of EDIT-401
2026-10-08 · Wells Fargo Upgrades Editas Medicine to Overweight From Equal Weight, $6 Price Target
2026-10-08 · Editas Medicine Receives Approval in Australia for Phase 3 Trial of EDIT-401 to Treat Hyperlipidemia
2026-09-23 · CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
2026-09-23 · CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
2026-09-23 · Guggenheim Upgrades Editas Medicine to Buy From Neutral, Price Target is $5
2026-09-15 · Top Premarket Gainers
2026-09-12 · Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
Price (daily)
Full chart · RSI · MACD · patterns